Reality Check on Epilepsy
Market access for epilepsy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Almost 29% of the covered lives under the pharmacy benefit in commercial formularies have utilization management restrictions on epilepsy medications
- Class Trends: Epidiolex, the first FDA-approved treatment that contains a purified drug substance derived from marijuana, is now available in the U.S.
- Key Findings: Many generic options are used in the treatment of seizures, while significant restrictions are observed for the most recently launched products
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.